Cancer Treatment Reviews
Volume 31, Issue 4 , Pages 303-311 , June 2005

Approaches to managing bone metastases from breast cancer: The role of bisphosphonates

  • Kyriaki Mystakidou

      Affiliations

    • Pain Relief and Palliative Care Unit, Department of Radiology, Areteion Hospital, School of Medicine, University of Athens, 27 Korinthias Street, 115 26 Athens, Greece
    • Corresponding Author InformationCorresponding author. Tel.: +30210 7707669; fax: +30210 7788437
    • ,
  • Emmanuela Katsouda

      Affiliations

    • Pain Relief and Palliative Care Unit, Department of Radiology, Areteion Hospital, School of Medicine, University of Athens, 27 Korinthias Street, 115 26 Athens, Greece
    • Tel.: +30210 7707669; fax: +30210 7788437.
    • ,
  • Evangelia Stathopoulou

      Affiliations

    • Roche(Hellas) S.A, 4Alamanas & Delfon Street, 15125 Maroussi, Athens, Greece
    • Tel: +30 210 6166220; fax: +30 6944940930.
    • ,
  • Lambros Vlahos

      Affiliations

    • Areteion Hospital, University of Athens, School of Medicine, Vas. Sofias 76, 115 28 Athens, Greece
    • Tel.: +30210 7286137.

References 

  1. Hortobagyi GN. Novel approaches to the management of bone metastases in patients with breast cancer. Semin Oncol. 2002;29(Suppl. 11):134–144
  2. Hortobagyi GN, Theriault RL, Porter L, et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Study Group. N Engl J Med. 1996;335:1785–1791
  3. Theriault RL, Lipton A, Hortobagyi GN, et al. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Study Group. J Clin Oncol. 1999;17:846–854
  4. Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev. 2001;27:165–176
  5. Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer. 2002;2:584–593
  6. Janjan N. Bone metastases: approaches to management. Semin Oncol. 2001;28:28–34
  7. Lipton A. Bone metastases in breast cancer. Curr Treat Options Oncol. 2003;4:151–158
  8. Body JJ, Bartl R, Burckhardt P, et al. Current use of bisphosphonates in oncology. J. Clin. Oncol. 1998;16(12):3890–3899
  9. Guarneri V, Conte PF. The curability of breast cancer and the treatment of advanced disease. Eur J Nucl Med Mol Imaging. 2004;31(Suppl. 1):S149–S161
  10. Kintzel PE. Anticancer drug-induced kidney disorders. Incidence, prevention and management. Drug Safety. 2001;24:19–38
  11. Paterson AHG, Powles TJ, Kanis JA, McCloskey E, Hanson J, Ashley S. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol. 1993;11:59–65
  12. Pavlakis N, Stockler M. Bisphosphonates for breast cancer. Cochrane Database Syst Rev. 2002;CD003474
  13. Jagdev SP, Purohito P, Heatley S, Herling C, Coleman RE. Comparison of the effect of intravenous pamidronate and oral clodronate on symptoms and bone resorption in patients with metastatic bone disease. Ann Oncol. 2001;12:1433–1438
  14. Mian M, Beghe F, Caprio A, Aloj R, Bertelli A. Tolerability and safety of clodronate therapy in bone diseases. Int J Clin Pharmacol Res. 1991;11:107–114
  15. Powles T, Paterson S, Kanis JA, et al. Randomized placebo-controlled trial of clodronate in patients with primary operable breast cancer. J Clin Oncol. 2002;20:3219–3224
  16. Falchi AM, Parmiggiani M, Cioni K, et al. Clodronate in the treatment of bone metastases secondary to breast cancer. Tumori. 1991;77(Suppl. 99):
  17. Ernst DS, Brasher P, Hagen N, Paterson AH, MacDonald RN, Bruera EA. A randomized, controlled trial of intravenous clodronate in patients with metastatic bone disease and pain. J Pain Symptom Manage. 1997;13:319–326
  18. Neri B, Gemelli MT, Sambataro S, et al. Subjective and metabolic effects of clodronate in patients with advanced breast cancer and symptomatic bone metastases. Anticancer Drugs. 1992;3:87–90
  19. Shparik J. Intravenous clodronate for metastatic bone pain in breast cancer. Breast Cancer Res Treat. 1996;37(Suppl.):75
  20. Heidenreich A, Hofmann R, Engelmann UH. The use of bisphosphonate for the palliative treatment of painful bone metastasis due to hormone refractory prostate cancer. J Urol. 2001;165:136–140
  21. Hillner BE, Ingle JN, Chlebowski RT, et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol. 2003;21:4042–4057
  22. Markowitz GS, Appel GB, Fine PL, et al. Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate. J Am Soc Nephrol. 2001;12:1164–1172
  23. Lockridge L, Papac RJ, Perazella MA. Pamidronate-associated nephrotoxicity in a patient with Langerhans’s histiocytosis. Am J Kidney Dis. 2002;40(Suppl. 1):E2
  24. Banerjee D, Asif A, Striker L, Preston RA, Bourgoignie JJ, Roth D. Short-term, high-dose pamidronate-induced acute tubular necrosis: the postulated mechanisms of bisphosphonate nephrotoxicity. Am J Kidney Dis. 2003;41(Suppl. 5):E18
  25. Novartis Pharma. Aredia® (pamidronate). UK prescribing information 2001
  26. Rosen LS, Gordon D, Kaminski M, et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J. 2001;7:377–387
  27. Rosen LS, Gordon DH, Dugan W, et al. Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer. 2004;100:36–43
  28. Rosen LS, Gordon D, Kaminski M, et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer. 2003;98:1735–1744
  29. Chang JT, Green L, Beitz J. Renal failure with the use of zoledronic acid. N Engl J Med. 2003;349:1676–1679
  30. Johnson KB, Gable P, Kaime EM, et al. Significant deterioration in renal function with the new bisphosphonate, zoledronic acid. Proc Am Soc Clin Oncol. 2003;22:46;[Abstract 2968]
  31. Stein SH, Davidson R, Tweed A, et al. Renal dysfunction with IV bisphosphonates in patients with metastatic breast cancer. Proc Am Soc Clin Oncol. 2003;22:46;[Abstract 2997]
  32. Novartis Pharma. Zometa® (zoledronic acid). European prescribing information. 2003
  33. Body JJ, Diel IJ, Lichinitser MR, et al. Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol. 2003;14:1399–1405
  34. Body JJ, Diel IJ, Lichinitser MR, et al. Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomized, placebo-controlled phase III studies. Br J Cancer. 2004;90:1133–1137
  35. Tripathy D, Budde M. Assessing the efficacy of ibandronate for the prevention of skeletal-related events (SREs) in metastatic bone disease: a methodological comparison. Bone. 2004;34(Suppl. 1):S91
  36. Body JJ, Tripathy D, Bergstrom B. Relief from metastatic bone pain with standard and intensive ibandronate dosing. Bone. 2004;34(Suppl. 1):S83
  37. F. Hoffmann-La Roche Ltd. Bondronat® (ibandronate). European prescribing information, 2003
  38. Pecherstorfer M, Diel IJ, Bergström B. Long-term (4-year) safety of intravenous ibandronate in metastatic breast cancer: an open-label study. Eur J Cancer Suppl. 2004;2:130
  39. Cameron D, Murray R, Tripathy D, Bergström B. Long-term safety of oral ibandronate in patients with skeletal metastases from breast cancer: 4-year follow-up data. Eur J Cancer Suppl. 2004;2:136
  40. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg. 2004;62:527–534
  41. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg. 2003;61:1115–1118
  42. Heidenreich A, Elert A, Hofmann R. Ibandronate in the treatment of prostate cancer associated painful osseous metastases. Prostate Cancer Prostatic Dis. 2002;5:231–235
  43. Heidenreich A, Ohlmann C, Olbert P, Hegele A. High-dose ibandronate is effective and well tolerated in the treatment of pain and hypercalcaemia due to metastatic urologic cancer. Eur J Cancer. 2003;1(Suppl. 5):S270
  44. Ohlmann C, Heidenreich A. Efficacy of ibandronate in the management of painful osseous metastases due to hormone refractory prostate cancer. Support Care Cancer. 2003;11:396;[Abstract A-38]
  45. Mancini I, Dumon JC, Body JJ. Efficacy and safety of ibandronate in the treatment of opioid-resistant bone pain associated with metastatic bone disease: a pilot study. J Clin Oncol. 2004;22:3587–3592
  46. Body J, Mancini I. Bisphosphonates for cancer patients: why, how, and when?. Support Care Cancer. 2002;10:399–407
  47. Brown JE, Cook RJ, Major P, et al. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst. 2005;97:59–69
  48. Coleman RE. The clinical use of bone resorption markers in patients with malignant bone disease. Cancer. 2002;94:2521–2533
  49. Garnero P. Markers of bone turnover in prostate cancer. Cancer Treat Rev. 2001;27(3):187–192discussion 193–196
  50. Major P, Cook R. Efficacy of bisphosphonates in the management of skeletal complications of bone metastases and selection of clinical endpoints. Am J Clin Oncol. 2002;25:S10–S18
  51. Liberato NL, Marchetti M, Barosi G. Clinical and economic issues in the treatment of advanced breast cancer with bisphosphonates. Drugs Aging. 2003;20(9):631–642
  52. Hutton J, De Cock E, Barrett-Lee P, Canney P, Body JJ, Neary M. Oral ibandronic acid versus intravenous zoledronic acid or intravenous generic pamidronate in patients with breast cancer and bone metastases in the UK: a cost-effectiveness modelling analysis. Breast Cancer Res Treat. 2004;88(Suppl. 1):S105;[Abstract 2086]
  53. Diel IJ, Solomayer EF. Bisphosphonates in the reduction of metastases in breast cancer–results of the extended follow-up of the first study population. Proc Am Soc Clin Oncol. 2000;19:[Abstract 314]
  54. Saarto T, Blomqvist C, Virkkunen P, Elomaa I. Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial. J Clin Oncol. 2001;19:10–17
  55. Jaschke A, Bastert G, Solomayer EF, et al. Adjuvant clodronate treatment improves the overall survival of primary breast cancer patients with micrometastases to bone marrow – a long-term follow-up. Proc Am Soc Clin Oncol. 2004;23:9;[Abstract 529]
  56. Powles T, Paterson A, McCloskey E, et al. Oral clodronate for adjuvant treatment of operable breast cancer: results of a randomized, double-blind, placebo-controlled multicenter trial. Proc Am Soc Clin Oncol. 2004;23:9;[Abstract 528]
  57. Saarto T, Vehmanen L, Blomqvist C, et al. Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment. Proc Am Soc Clin Oncol. 2004;23:8;[Abstract 527]
  58. Grant M, Hausmaninger H, Samonigg H, et al. Changes in bone mineral density caused by anastrazole or tamoxifen in combination with goserelin (±zoledronate) as adjuvant treatment for hormone receptor positive premenopausal breast cancer: results of a randomised multicenter trial. Breast Cancer Res Treat. 2002;76(Suppl. 1):S31
  59. Theriault R, Jakesz R, Gnant M, et al. The evolving role of bisphosphonates for the prevention of cancer treatment-induced bone loss in patients with breast cancer. Bone. 2004;34(Suppl. 1):S90
  60. Coleman R, Gralow J, Bell R, et al. Zoledronic acid is being investigated for the prevention of bone metastases in patients with early stage breast cancer. Bone. 2004;34(Suppl. 1):S85
  61. Powles TJ, McCloskey E, Paterson AH, et al. Oral clodronate and reduction in loss of bone mineral density in women with operable primary breast cancer. J Natl Cancer Inst. 1998;90:704–708
  62. Vehmanen L, Saarto T, Elomaa I, et al. Long-term impact of chemotherapy-induced ovarian failure on bone mineral density (BMD) in premenopausal breast cancer patients. The effect of adjuvant clodronate treatment. Eur J Cancer. 2001;37:2373–2378
  63. Rizzoli R, Forni M, Schaad MA, et al. Effects of oral clodronate on bone mineral density in patients with relapsing breast cancer. Bone. 1996;18:531–537
  64. Saarto T, Blomqvist C, Valimaki M, et al. Clodronate improves bone mineral density in post-menopausal breast cancer patients treated with adjuvant antioestrogens. Br J Cancer. 1997;75:602–605
  65. Lipton A. Toward new horizons: the future of bisphosphonate therapy. Oncologist. 2004;9(Suppl. 4):38–47
  66. Wittrant Y, Theoleyre S, Chipoy C, et al. RANKL/RANK/OPG: new therapeutic targets in bone tumours and associated osteolysis. Biochim Biophys Acta. 2004;1704(2):49–57
  67. McPartland C, Jackson G, Grosjean L. Palliative management of metastatic bone pain in Europe and Canada: the role of bisphosphonates. Support Care Cancer. 2004;12:401–402(A-110)
  68. Johnson G, Gralow J, Benson P. Use of bisphosphonates for the palliative management of metastatic bone pain in the US. Support Care Cancer. 2004;12:400;(A-105)

PII: S0305-7372(05)00055-1

doi: 10.1016/j.ctrv.2005.03.005

Cancer Treatment Reviews
Volume 31, Issue 4 , Pages 303-311 , June 2005

Article Tools